<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425307</url>
  </required_header>
  <id_info>
    <org_study_id>H-28572 TWiTCH</org_study_id>
    <secondary_id>R01HL095647</secondary_id>
    <nct_id>NCT01425307</nct_id>
  </id_info>
  <brief_title>Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea</brief_title>
  <acronym>TWiTCH</acronym>
  <official_title>TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of The King's Daughters</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospitals and Clinics of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steven and Alexandra Cohen Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative therapy
      (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle cell
      anemia and abnormally high (≥200 cm/sec) Transcranial Doppler (TCD) velocities, who currently
      receive chronic transfusions to reduce the risk of primary stroke. For the alternative
      treatment regimen (hydroxyurea) to be declared non-inferior to the standard treatment regimen
      (transfusions), after adjusting for baseline differences, the hydroxyurea-treated group must
      have a mean TCD velocity similar to that observed with transfusion prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the clear results of the STOP and the follow-up STOP II trials, the use of chronic
      erythrocyte transfusions for primary stroke prevention in children with Sickle Cell Anemia
      (SCA) remains controversial for many practicing hematologists, as well as for patients and
      families. Transfusions have proven clinical efficacy in preventing first stroke in children
      with SCA and abnormal TCD velocities, but their indefinite use may still be difficult to
      justifY.

      The risk of transfusion acquired iron overload is now recognized as a serious consequence of
      chronic erythrocyte transfusions in children with SCA. After one to two years of monthly
      transfusions, virtually every patient will have excess hepatic iron deposition that warrants
      intervention with chelation therapy. The effectiveness of iron chelation has not yet been
      realized, despite the availability of the oral chelator deferasirox (Exjade®), due to its
      lack of palatability and increasing recognition of serious drug-related toxicities including
      renal and hepatic dysfunction. Simply put, indefinite erythrocyte transfusions cannot be
      viewed as adequate and acceptable long-term therapy for primary stroke prevention in SCA.
      There is an urgent need to develop an equivalent effective alternative therapy for the
      prevention of primary stroke in children with SCA, specifically one that better manages iron
      overload and improves quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped early due to successfully meeting the primary endpoint
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side</measure>
    <time_frame>Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).</time_frame>
    <description>The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TCD Time-averaged Mean Velocity on the Non-index Side</measure>
    <time_frame>24 months</time_frame>
    <description>This secondary endpoint for the TWiTCH trial will be maximum TCD time-averaged mean velocity on the non-index side. The non-index side is the side with the lower mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the secondary endpoint will be obtained at clinic visits during baseline and during the 24-month treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Stroke Events</measure>
    <time_frame>24 months</time_frame>
    <description>This secondary outcome measure will compare standard to alternative therapy for primary stroke events (a) primary ischemic stroke; b) primary hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-stroke Neurological Events</measure>
    <time_frame>24 months</time_frame>
    <description>This secondary objective will compare standard to alternative treatment for the incidence of non-stroke neurological events. Data for this outcome will be collected through entry and exit neurological exams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Baseline in Hepatic Iron Overload as Assessed by Serum Ferritin</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>Standard Quality of Life measure will be taken during specific time points as well as one newly developed Sickle Cell Disease-specific test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be measured using Barthel Index testing at the beginning, middle, and end of the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Decline</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be measured using standardized neurocognitive tests at baseline and exit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth and Development</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be measured by capturing height and weight monthly and conducting an annual pubertal assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Transfusion Events</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be recorded on every interval visit form through questions asking whether there have been transfusion complications. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hydroxyurea Toxicities</measure>
    <time_frame>24 Months</time_frame>
    <description>This measure will be performed on a monthly basis throughout the trial by recording the CBC and retic count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Phlebotomy Complications</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be recorded on every interval visit form through questions asking whether there have been phlebotomy complications. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Liver MRI Complications</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will be recorded through questions asking whether there have been Liver MRI complications at baseline, middle, and end of treatment. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Baseline in Hepatic Iron Overload as Assessed by Liver Iron Concentration</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Therapy of monthly transfusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxyurea will be provided as capsules or liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Hydroxycarbamide</other_name>
    <other_name>Hydrea</other_name>
    <other_name>Droxia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pediatric subjects with severe forms of sickle cell anemia (HbSS, HbSβ0
             thalassemia,HbSOArab)

          2. Age range of 4.0-15.99 years, inclusive, at the time of enrollment

          3. Documented index (pre-treatment) abnormally high TCD Velocity by Transcranial Doppler
             ultrasonography. An abnormally high index TCD is defined as TCD V greater than or
             equal to 200 cm/sec, or abnormally high TCDi V greater than or equal to185cm/sec, or
             TCD maximum V greater than or equal to 250 cm/sec.

          4. At least 12 months of chronic monthly erythrocyte transfusions since the index
             abnormal TCD examination

          5. Adequate monthly erythrocyte transfusions with average HbS less than or equal to 45%
             (the upper limit of the established academic community standard) for the past 6 months
             before enrollment

          6. Parent or guardian willing and able to provide informed consent with verbal or written
             assent from the child

          7. Ability to comply with study related treatments, evaluations, and follow-up

        Exclusion Criteria:

          1. Completed overt clinical stroke or TIA

          2. Inability to obtain TCD velocities due to anatomical abnormalities such as a)
             Inadequate bone windows b) Previous revascularization procedures (e.g., EDAS)

          3. Known severe vasculopathy or moya-moya disease on brain MRA

          4. Inability to receive or tolerate chronic red blood cell (RBC) transfusion therapy, due
             to any of the following: a) Multiple RBC alloantibodies making cross-matching
             difficult or impossible b) RBC autoantibodies making cross-matching difficult or
             impossible c) Religious objection to transfusions that preclude their chronic use d)
             Non-compliance with transfusions over the past 6 months before enrollment (temporary
             exclusion)

          5. Inability to take or tolerate daily oral hydroxyurea, including a) Known allergy to
             hydroxyurea therapy b) Positive serology to HIV infection c) Malignancy d) Current
             lactation e) Previous stem cell transplant or other myelosuppressive therapy

          6. Clinical and laboratory evidence of hypersplenism (temporary exclusions): a) Palpable
             splenomegaly greater than 5cm below the left costal margin AND b) Transfusion
             requirement greater than 250 mL/kg over the previous 12 months

          7. Abnormal laboratory values at initial evaluation (temporary exclusions): a)
             Pre-transfusion hemoglobin concentration less than 8.0 gm/dL b) WBC count less than
             3.0 x 10^9/L c) Absolute neutrophil count (ANC) less than 1.5 x 10^9/L d) Platelet
             count less than 100 x 10^9/L e) Serum creatinine more than twice the upper limit for
             age OR greater than or equal to 1.0 mg/dL

          8. Current participation in other therapeutic clinical trials

          9. Current use of other therapeutic agents for sickle cell disease (e.g., arginine,
             decitabine, magnesium). Subjects must have been off hydroxyurea for at least 3- months
             prior to enrollment.

         10. Any condition or chronic illness, such as a positive tuberculin (PPD) test, which in
             the opinion of the CI makes participation ill-advised.

         11. Inability or unwillingness to complete required screening and exit studies, including
             TCD ultrasonography, brain MRI/MRA, liver MRI and blood tests.

         12. A sibling enrolled in TWiTCH

         13. Pregnancy or unwillingness to use a medically acceptable form of contraception if
             sexually active (male OR female).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell E. Ware, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <results_first_submitted>April 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase III</keyword>
  <keyword>Sickle cell anemia</keyword>
  <keyword>Abnormally high Transcranial Doppler velocities.</keyword>
  <keyword>Reduce risk of primary stroke</keyword>
  <keyword>Pediatric patients</keyword>
  <keyword>Chelation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase 3 First Patient In: 16-Sep-2011; Last Patient Last Visit 10-Feb-2015
26 medical institutions in the United States of America and Canada</recruitment_details>
      <pre_assignment_details>159 were enrolled. 121 met eligibility criteria and randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Therapy</title>
          <description>Standard Therapy of monthly transfusions</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm</title>
          <description>Hydroxyurea will be provided as capsules or liquid
Hydroxyurea: Capsules (300 mg, 400 mg, or 500 mg) taken once daily or liquid formulation (100 mg/mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61">Randomized Sample: 61; Intention-to Treat Sample:61</participants>
                <participants group_id="P2" count="60">Randomized Sample: 60; Intention-to Treat Sample:60</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42">Treatment Phase: 42; 6-Month Follow up: 58</participants>
                <participants group_id="P2" count="41">Treatment Phase: 41; 6-Month Follow-up:59</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Therapy</title>
          <description>Standard Therapy of monthly transfusions</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm</title>
          <description>Hydroxyurea will be provided as capsules or liquid
Hydroxyurea: Capsules (300 mg, 400 mg, or 500 mg) taken once daily or liquid formulation (100 mg/mL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="2.6"/>
                    <measurement group_id="B2" value="9.7" spread="3.2"/>
                    <measurement group_id="B3" value="9.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Index TCD</title>
          <description>The index TCD is the documented first abnormal TCD examination. This TCD examination was at least 12 months prior to eligibility for TWiTCH.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="2.0"/>
                    <measurement group_id="B2" value="5.0" spread="1.8"/>
                    <measurement group_id="B3" value="5.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Transfusions</title>
          <description>Duration of Transfusions refers to the duration of chronic transfusion therapy (either simple, partial exchange or erythrocytapheresis) for primary stroke prevention.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.8"/>
                    <measurement group_id="B2" value="4.5" spread="2.8"/>
                    <measurement group_id="B3" value="4.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side</title>
        <description>The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period.</description>
        <time_frame>Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Hydroxyurea will be provided as capsules or liquid
Hydroxyurea: Capsules (300 mg, 400 mg, or 500 mg) taken once daily or liquid formulation (100 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy</title>
            <description>Standard Therapy of monthly transfusions</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side</title>
          <description>The primary endpoint for the TWiTCH trial was the difference between the treatment groups of the maximum TCD TAMV on the index side, calculated from a mixed model. The index side is the side with the higher mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the TAMV on the index site were obtained at clinic visits during baseline and during the treatment period.</description>
          <population>Intention-to-Treat</population>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="135" upper_limit="142"/>
                    <measurement group_id="O2" value="143" lower_limit="140" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Participants were randomized at a central site, stratified by site with a block size of four, and an adaptive randomization scheme was used to balance the covariates of baseline age and TCD velocity. The treatment period lasted 24 months. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-to-treat population.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>We hypothesized that the Alternative arm mean TCD velocity at 24 months will be less than the Standard arm mean TCD velocity plus 15cm/sec. We used Lan-DeMets boundaries to control overall Type I error rate at α = 0.05. For looks at exactly 1/3, 2/3, and 100 percent of the completed subjects, the cumulative α were estimated to be 0.0001, 0.001, and 0.05, respectively.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P value for non inferiority was 8.82 X 10^-16</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>8.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TCD Time-averaged Mean Velocity on the Non-index Side</title>
        <description>This secondary endpoint for the TWiTCH trial will be maximum TCD time-averaged mean velocity on the non-index side. The non-index side is the side with the lower mean (averaged over baseline evaluations) of the maximum (over arteries on that side) TCD time-averaged velocity. Values of the secondary endpoint will be obtained at clinic visits during baseline and during the 24-month treatment period.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Stroke Events</title>
        <description>This secondary outcome measure will compare standard to alternative therapy for primary stroke events (a) primary ischemic stroke; b) primary hemorrhagic stroke</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-stroke Neurological Events</title>
        <description>This secondary objective will compare standard to alternative treatment for the incidence of non-stroke neurological events. Data for this outcome will be collected through entry and exit neurological exams.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Baseline in Hepatic Iron Overload as Assessed by Serum Ferritin</title>
        <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>Standard Therapy of monthly transfusions</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Hydroxyurea will be provided as capsules and liquid</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Baseline in Hepatic Iron Overload as Assessed by Serum Ferritin</title>
          <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
          <units>ng per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38" spread="2095"/>
                    <measurement group_id="O2" value="-1805" spread="1651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Quality of Life</title>
        <description>Standard Quality of Life measure will be taken during specific time points as well as one newly developed Sickle Cell Disease-specific test.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status</title>
        <description>This outcome will be measured using Barthel Index testing at the beginning, middle, and end of the treatment period.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Decline</title>
        <description>This outcome will be measured using standardized neurocognitive tests at baseline and exit.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth and Development</title>
        <description>This outcome will be measured by capturing height and weight monthly and conducting an annual pubertal assessment.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Transfusion Events</title>
        <description>This outcome will be recorded on every interval visit form through questions asking whether there have been transfusion complications. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hydroxyurea Toxicities</title>
        <description>This measure will be performed on a monthly basis throughout the trial by recording the CBC and retic count.</description>
        <time_frame>24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Phlebotomy Complications</title>
        <description>This outcome will be recorded on every interval visit form through questions asking whether there have been phlebotomy complications. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Liver MRI Complications</title>
        <description>This outcome will be recorded through questions asking whether there have been Liver MRI complications at baseline, middle, and end of treatment. Any complication higher than a CTCAE grade 2 event will be reported as a SAE.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <time_frame>24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Baseline in Hepatic Iron Overload as Assessed by Liver Iron Concentration</title>
        <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy</title>
            <description>Standard Therapy of monthly transfusions</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm</title>
            <description>Hydroxyurea will be provided as capsules and liquid</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Baseline in Hepatic Iron Overload as Assessed by Liver Iron Concentration</title>
          <description>This secondary objective will compare standard to alternative therapy for hepatic iron overload.</description>
          <population>Participants with available data</population>
          <units>mg FE per g dry weight liver</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="8.7"/>
                    <measurement group_id="O2" value="-1.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Therapy</title>
          <description>Standard Therapy of monthly transfusions</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm</title>
          <description>Hydroxyurea will be provided as capsules or liquid
Hydroxyurea: Capsules (300 mg, 400 mg, or 500 mg) taken once daily or liquid formulation (100 mg/mL)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-occlusive Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Splenomeagaly/Splenectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle Cell Anemia with Crisis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="62" subjects_affected="24" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrxia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Viral Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" events="30" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotranferase</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotranserase</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="37" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coombs Direct Test Positive</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hemoglobin Decreased</sub_title>
                <counts group_id="E1" events="66" subjects_affected="25" subjects_at_risk="61"/>
                <counts group_id="E2" events="76" subjects_affected="32" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Reticulocyte Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="19" subjects_at_risk="61"/>
                <counts group_id="E2" events="41" subjects_affected="22" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sleep Apnea Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Poor Venous Access</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Further analysis is required to verify that the Adverse Events are accurately represented.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Barry Robert Davis</name_or_title>
      <organization>The University of Texas School of Public Health</organization>
      <phone>713-500-9515</phone>
      <email>barry.r.davis@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

